Navigation Links
BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
Date:8/13/2008


Toronto Stock Exchange Symbol: MS

- Milestone triggers $10 million payment from Eli Lilly and Company -

EDMONTON, Aug. 13 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Drug Safety Monitoring Board (DSMB) for the MAESTRO-01 trial has conducted the scheduled interim analysis of efficacy and safety and has recommended that the trial continue to completion. MAESTRO-01 is the pivotal phase II/III Canadian and European study of dirucotide (MBP8298) in patients with secondary progressive MS.

The interim analysis included patients from the first 200 to complete MAESTRO-01 and assessed the likelihood of the study reaching its primary endpoint at the end of the trial in MS patients with the target HLA-DR2 and/or HLA-DR4 immune response genes. The DSMB analysis also included a scheduled review of safety information.

Based on the DSMB decision, Eli Lilly and Company has agreed to provide the $10 million milestone payment to BioMS as part of the terms of the licensing and collaboration agreement.

"We are very encouraged by the safety board's recommendation," said Kevin Giese, President and CEO of BioMS Medical. "This positive review is an important milestone for BioMS and our partner, Eli Lilly and Company, and moves us one step closer to our goal of bringing this important therapy to multiple sclerosis patients."

"We are pleased by the results of the interim analysis and look forward to final efficacy and safety data from this trial next year," said Dr. Mark Freedman, Professor of Neurology at the University of Ottawa and Director of the MS Research Clinic at the Ottawa Hospital. "If successful, this novel therapy administered only twice per year, could help a large underserved population with late stage MS."

About MAESTRO-01

----------------

Dirucotide (MBP8298) is being studied in fo
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMS Medical Announces Second Quarter 2008 Results
2. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
3. BioMS Medical to present at BMO Healthcare Conference
4. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. BioMS Medical to present at Jefferies Healthcare Conference
6. BioMS Medical to present at 2008 BIO International Convention
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medical announces first quarter 2008 results
9. BioMs Medical to present at TIDES(R) Conference
10. BioMS Medical to present at Rodman and Renshaw Global Healthcare Conference
11. BioMS Medical Provides Update On Pipeline Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... IN (PRWEB) August 22, 2014 The ... community and its members in Alaska that Alaska Governor ... Concurrent Resolution 15, further defining public use of Unmanned ... Systems Task Force. House Bill 255states that it is, ... to images captured by an unmanned aircraft system.” It ...
(Date:8/22/2014)... Los Angeles (PRWEB) August 22, 2014 ... for age-defying products, is in the spotlight again. ... night cream and its NeriumFirmTM Body Contouring Cream ... presented by Backstage Creations during the 66th Primetime ... the patented NAE-8® extract, third-party clinical trials show ...
(Date:8/22/2014)... The identification of protein-coding variants ... accelerated by exome sequencing. Built on Roche NimbleGen’s ... SeqCap EZ Developer system has been a proven ... additionally present how he achieved coverage statistics similar ... mouse exome kits. With over 236,000 SNPs and ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 “Our ... acknowledgement is a national disgrace. Furthermore, every governmental ... establishing the current, deplorable state of unorganized dysfunction ... great mistakes," to merely serve as a device ... extent of colossal failure(s) that have accumulated through ...
Breaking Biology Technology:State of Alaska Signs Unmanned Aircraft Systems Bill 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 3Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 25 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2
... LOUIS, Oct. 17 Monsanto Company (NYSE:,MON) today ... Grant,chairman, president and chief executive officer, and Robb ... established stock trading,plans in accordance with Rule 10b5-1 ... these plans, the Monsanto executives have directed brokers ...
... and OSAKA, Japan, Oct. 17 Affymax,Inc. (Nasdaq: ... (TSE: 4502),today announced that they have been awarded ... Executives Society of the U.S. and Canada (LES),for ... lead product candidate, Hematide(TM), for the treatment of,anemia. ...
... Penn., Oct. 17 Respironics, Inc.,(Nasdaq: RESP ... market,announced today that it intends to release its ... 2007 on Thursday October 25, 2007. In,conjunction with ... and,business outlook, Respironics will host a conference call ...
Cached Biology Technology:Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia 2Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia 3Respironics to Webcast Fiscal 2008 First Quarter Conference Call 2
(Date:8/22/2014)... German . , ... fixated in a way so as to align themselves ... Fudan University researchers are planning on looking into how ... are being published today in the scientific journal ... molecules. Everyone knows that at least from having ...
(Date:8/22/2014)... rhino reproduction in Europe highlights how hormone analysis ... Researchers from Chester Zoo, The University of Manchester ... six-year study which encompassed 90% of European population ... the research as part of her PhD at ... black rhinoceros breed well in captivity, not all ...
(Date:8/22/2014)... antioxidants and can reduce free radical damage. ... oxidative stress? Jianbo Zhao and co-workers from ... University, China discovered that green tea polyphenol ... apoptosis, indicating green tea polyphenols play a ... oxidative stress. The relevant study has been ...
Breaking Biology News(10 mins):Proteins: New class of materials discovered 2Hormone analysis helps identify horny rhinos 2
... A study from scientists at Queen Mary, University of London, ... or go through major surgery, can suffer organ damage in ... injury. The study, published today in Nature Immunology ... move out of blood vessels to defend damaged organs against ...
... in Nature Photonics , U of T Engineering researchers report ... coatings that efficiently convert the sun,s rays to electricity. The ... first efficient tandem solar cell based on colloidal quantum dots (CQD). ... layers one tuned to capture the sun,s visible rays, the ...
... cover in the northern U.S. and into Canada as a factor ... new study by researchers at the University of Georgia indicates they ... It turns out that snow piling up over a band of ... effect on the climate of the U.S. as the much-better-known El ...
Cached Biology News:Rogue blood cells may contribute to post-surgery organ damage 2U of T researchers crack full-spectrum solar challenge 2Northern Eurasian snowpack could be a predictor of winter weather in US, team from UGA reports 2
Goat polyclonal to PPP2R5D Immunogen: Peptide with sequence KRAEEFLTASQEAL, from C Terminus of the protein sequence according to NP_006236...
Rabbit polyclonal to KIAA1276 ( Abpromise for all tested applications). entrezGeneID: 27146 SwissProtID: Q9ULE4...
Mouse monoclonal [LH8] to Cytokeratin 5 + 14 ( Abpromise for all tested applications). entrezGeneID: 3852 SwissProtID: P02533...
Rabbit polyclonal to IL23 P19 ( Abpromise for all tested applications). Antigen: Synthetic 16 amino acid peptide from near the amino terminus of human IL23 P19 Entrez Gene ID: 51561 Swiss...
Biology Products: